Pulike (603566.SH) announced that the “Porcine circovirus type 2 baculovirus vector and Mycoplasma pneumoniae bivalent inactivated vaccine,” jointly applied for by its wholly owned subsidiary Huizhong Biotech and other entities, was approved by the Ministry of Agriculture and Rural Affairs as a new veterinary drug, and a New Veterinary Drug Registration Certificate was issued. The vaccine is used to prevent porcine circovirus type 2 infection and porcine mycoplasmal pneumonia, and offers advantages including high antigen purity, mild adverse reactions, and dual protection in one injection. This certificate enriches the company’s porcine vaccine product line and is expected to enhance product competitiveness and provide a new source of earnings growth. A veterinary drug product approval number is still required before the product can be marketed.